Summary

Thyroid Gland Disorders Treatment Market – Scope of Report
TMR’s report on the global thyroid gland disorders treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global thyroid gland disorders treatment market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global thyroid gland disorders treatment market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the thyroid gland disorders treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global thyroid gland disorders treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global thyroid gland disorders treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global thyroid gland disorders treatment market.

The report delves into the competitive landscape of the global thyroid gland disorders treatment market. Key players operating in the global thyroid gland disorders treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global thyroid gland disorders treatment market profiled in this report.

Key Questions Answered in Global thyroid gland disorders treatment Market Report
• What is the sales/revenue generated by thyroid gland disorders treatment across all regions during the forecast period?
• What are the opportunities in the global thyroid gland disorders treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Thyroid Gland Disorders Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global thyroid gland disorders treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global thyroid gland disorders treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global thyroid gland disorders treatment market.

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Thyroid Gland Disorders Treatment Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Thyroid Gland Disorders Treatment Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. List of Types of Thyroid Gland Disorder Tests
5.3. Disorder Prevalence & Incidence Rate Globally With Key Countries
5.4. COVID-19 Pandemic Impact on Industry
6. Thyroid Gland Disorders Treatment Market Analysis and Forecast, by Disorder
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disorder, 2023-2031
6.3.1. Hypothyroidism
6.3.1.1. Levothyroxine
6.3.1.2. Liothyronine
6.3.2. Hyperthyroidism
6.3.2.1. Imidazole
6.3.2.2. Propacil
6.4. Market Attractiveness, by Disorder
7. Global Thyroid Gland Disorders Treatment Market Analysis and Forecast, by Region
7.1. Key Findings
7.2. Market Value Forecast, by Region, 2023-2031
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Market Attractiveness, by Region
8. North America Thyroid Gland Disorders Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value Forecast, by Disorder, 2023-2031
8.2.1. Hypothyroidism
8.2.1.1. Levothyroxine
8.2.1.2. Liothyronine
8.2.2. Hyperthyroidism
8.2.2.1. Imidazole
8.2.2.2. Propacil
8.3. Market Attractiveness, by Disorder
8.4. Market Value Forecast, by Country, 2023–2031
8.4.1. U.S.
8.4.2. Canada
8.5. Market Attractiveness Analysis
8.5.1. By Disorder
8.5.2. By Country
9. Europe Thyroid Gland Disorders Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Disorder, 2023-2031
9.2.1. Hypothyroidism
9.2.1.1. Levothyroxine
9.2.1.2. Liothyronine
9.2.2. Hyperthyroidism
9.2.2.1. Imidazole
9.2.2.2. Propacil
9.3. Market Attractiveness, by Disorder
9.4. Market Value Forecast, by Country/Sub-region, 2023–2031
9.4.1. Germany
9.4.2. U.K.
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Rest of Europe
9.5. Market Attractiveness Analysis
9.5.1. By Disorder
9.5.2. By Country/Sub-region
10. Asia Pacific Thyroid Gland Disorders Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Disorder, 2023-2031
10.2.1. Hypothyroidism
10.2.1.1. Levothyroxine
10.2.1.2. Liothyronine
10.2.2. Hyperthyroidism
10.2.2.1. Imidazole
10.2.2.2. Propacil
10.3. Market Attractiveness, by Disorder
10.4. Market Value Forecast, by Country/Sub-region, 2023-2031
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia & New Zealand
10.4.5. Rest of Asia Pacific
10.5. Market Attractiveness Analysis
10.5.1. By Disorder
10.5.2. By Country/Sub-region
11. Latin America Thyroid Gland Disorders Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Disorder, 2023-2031
11.2.1. Hypothyroidism
11.2.1.1. Levothyroxine
11.2.1.2. Liothyronine
11.2.2. Hyperthyroidism
11.2.2.1. Imidazole
11.2.2.2. Propacil
11.3. Market Attractiveness, by Disorder
11.4. Market Value Forecast, by Country/Sub-region, 2023-2031
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Market Attractiveness Analysis
11.5.1. By Disorder
11.5.2. By Country/Sub-region
12. Middle East & Africa Thyroid Gland Disorders Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Disorder, 2023-2031
12.2.1. Hypothyroidism
12.2.1.1. Levothyroxine
12.2.1.2. Liothyronine
12.2.2. Hyperthyroidism
12.2.2.1. Imidazole
12.2.2.2. Propacil
12.3. Market Attractiveness, by Disorder
12.4. Market Value Forecast, by Country/Sub-region, 2023-2031
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of Middle East & Africa
12.5. Market Attractiveness Analysis
12.5.1. By Disorder
12.5.2. By Country/Sub-region
13. Competition Landscape
13.1. Market Player – Competition Matrix (By Tier and Size of Companies)
13.2. Market Share Analysis, by Company (2022)
13.3. Company Profiles
13.3.1. Merck KGaA
13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.1.2. Disorder Portfolio
13.3.1.3. Financial Overview
13.3.1.4. SWOT Analysis
13.3.1.5. Strategic Overview
13.3.2. Pfizer, Inc.
13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.2.2. Disorder Portfolio
13.3.2.3. Financial Overview
13.3.2.4. SWOT Analysis
13.3.2.5. Strategic Overview
13.3.3. Takeda Pharmaceutical Company Ltd.
13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.3.2. Disorder Portfolio
13.3.3.3. Financial Overview
13.3.3.4. SWOT Analysis
13.3.3.5. Strategic Overview
13.3.4. Allergan
13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.4.2. Disorder Portfolio
13.3.4.3. Financial Overview
13.3.4.4. SWOT Analysis
13.3.4.5. Strategic Overview
13.3.5. Sanofi S.A.
13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.5.2. Disorder Portfolio
13.3.5.3. Financial Overview
13.3.5.4. SWOT Analysis
13.3.5.5. Strategic Overview
13.3.6. AbbVie Inc.
13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.6.2. Disorder Portfolio
13.3.6.3. Financial Overview
13.3.6.4. SWOT Analysis
13.3.6.5. Strategic Overview
13.3.7. Lannet Company, Inc.
13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.7.2. Disorder Portfolio
13.3.7.3. Financial Overview
13.3.7.4. SWOT Analysis
13.3.7.5. Strategic Overview
13.3.8. Aspen
13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.8.2. Disorder Portfolio
13.3.8.3. Financial Overview
13.3.8.4. SWOT Analysis
13.3.8.5. Strategic Overview